Royalty Pharma/$RPRX
Royalty Pharma's stock falls after update that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint, limiting expected royalty returns.
3 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Royalty Pharma
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Ticker
- $RPRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 100
- Headquarters
- New York, United States
- Website
- www.royaltypharma.com
Royalty Pharma Metrics
BasicAdvanced
$28B
34.31
$1.86
0.43
$0.91
1.47%
Price and volume
Market cap
$28B
Beta
0.43
52-week high
$64.38
52-week low
$34.08
Average daily volume
2.7M
Dividend rate
$0.91
Financial strength
Current ratio
2.797
Quick ratio
2.786
Long term debt to equity
87.698
Total debt to equity
91.581
Dividend payout ratio (TTM)
49.10%
Interest coverage (TTM)
4.30%
Profitability
EBITDA (TTM)
1,571.074
Gross margin (TTM)
95.82%
Net profit margin (TTM)
32.02%
Operating margin (TTM)
61.76%
Revenue per employee (TTM)
$25,360,000
Management effectiveness
Return on assets (TTM)
5.13%
Return on equity (TTM)
13.97%
Valuation
Price to earnings (TTM)
34.307
Price to revenue (TTM)
10.985
Price to book
4.17
Price to tangible book (TTM)
4.82
Price to free cash flow (TTM)
48.246
Free cash flow yield (TTM)
2.07%
Free cash flow per share (TTM)
1.326
Dividend yield (TTM)
1.42%
Forward dividend yield
1.47%
Growth
Revenue change (TTM)
10.01%
Earnings per share change (TTM)
-19.98%
3-year revenue growth (CAGR)
2.41%
3-year earnings per share growth (CAGR)
48.12%
3-year dividend per share growth (CAGR)
5.27%
What the Analysts think about Royalty Pharma
Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.
Analyst projections of the future price of Royalty Pharma stock.
Bulls say / Bears say
Royalty Pharma delivered strong Q2 execution, with Royalty Receipts up 14% to $768 million, operating cash flow doubling to $728 million, and 2026 Portfolio Receipts guidance raised to $3.4 billion–$3.5 billion. (SEC)
The company is actively replenishing its long-duration pipeline: announced transaction value reached $1.7 billion and capital deployment $1.1 billion by August 4, 2026, while the development-stage portfolio expanded to 19 potential therapies after acquiring a royalty on AstraZeneca’s cliramitug. (SEC)
Recent transactions add potential future growth with limited direct operating burden, including funding agreements tied to rusfertide, JNJ-4804 and cliramitug; the cliramitug deal provides exposure to a Phase 3 therapy targeting a large and growing ATTR-CM market. (Royalty Pharma)
Pelacarsen failed to meet its Phase 3 primary cardiovascular endpoint, eliminating the program’s expected upside for Royalty Pharma; management says the investment should still generate a modest positive return through the underlying Spinraza royalty. (Royalty Pharma)
Royalty Pharma had $9.2 billion of debt against $812 million of cash as of June 30, 2026, while 2026 interest expense is expected at approximately $350 million–$360 million, leaving earnings and capital-allocation flexibility sensitive to leverage. (SEC)
Several established royalties are showing pressure: Imbruvica receipts declined 16% year over year in Q2 2026, while Promacta was adversely affected by U.S. generic competition; this highlights the need for newer assets to offset product-specific erosion. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Royalty Pharma Financial Performance
Revenues and expenses
Royalty Pharma Earnings Performance
Company profitability
Upcoming events
Royalty Pharma News
AllArticlesVideos
Funds containing Royalty Pharma
AllUSDGBPEUR
Fund name | Fund size | $RPRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.86% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.86% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.57% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.17% |
iShares MSCI USA SRI€QDVR | €2.9B | 0.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.